News

The biotechnology company CureVac has announced that its Phase IIb/III clinical trial of the COVID-19 vaccine candidate CVnCoV demonstrates an interim efficacy of 47%.

In a study, scientists found that infection with a specific coronavirus strain reactivated dormant Mycobacterium tuberculosis in mice.

A new study looking at the way human cells activate the immune system in response to SARS-CoV-2 infection could open the door to even more effective and powerful vaccines against the coronavirus and its rapidly emerging variants keeping the global pandemic smoldering.

Researchers are using a bifunctional protein as a "bridge" between natural killer cells and breast cancer cells. This strategy could help to develop a novel breast cancer-specific immunotherapy.

The biotechnology company Novavax has announced that its Phase III clinical trial of the COVID-19 vaccine NVX-CoV2373 demonstrated an overall efficacy of 90.4%.

Research suggests that two compounds originating from hops can help thwart a dangerous buildup of fat in the liver known as hepatic steatosis.

Multiple efforts aim to increase COVID-19 vaccine access and acceptance among Black, Indigenous and people of color communities.

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalized with severe COVID-19 who have not mounted a natural antibody response of their own.

Researchers have created a quantum microscope that can reveal biological structures that would otherwise be impossible to see.

A study reports that the Ad26.COV2.S vaccine induced immune responses against all viral variants.